Novo says Victoza bests MSD’s Januvia at lowering blood sugar

pharmafile | April 4, 2016 | News story | Research and Development Novo Nordisk, Victoza 

Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – a measure of high blood sugar.

The 26-week 407-patient LIRA-SWITCH trial assessed the effects of switching from Januvia (sitagliptin) plus metformin to Victoza (liraglutide) plus metformin.

The study showed that patients who switched to Victoza achieved a superior reduction in HbA1c compared to those who remained on Januvia: 1.14% versus 0.54%.

Additionally, adults who switched to Victoza experienced significantly greater body weight reductions compared to those who continued with their sitagliptin dose – at 3.31 kg versus 1.64 kg.

“The LIRA-SWITCH trial results provide valuable insight that adults uncontrolled on sitagliptin may achieve a superior HbA1c reduction with liraglutide 1.8 mg versus continuing on sitagliptin treatment,” says Dr Maximo Maislos, director of Western Negev Mobile Diabetes Clinic Program, and investigator of the LIRA-SWITCH trial. “These findings are valuable, as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy.”

More adults with type 2 diabetes treated with Victoza achieved their HbA1c targets, compared to those on sitagliptin, at 50.6% versus 26.9%. Victoza patients also demonstrated significantly greater reductions in fasting plasma glucose vs those treated with sitagliptin: 1.84 versus 0.73.

Joel Levy

Related Content


Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …

Novo Nordisk partners with UNICEF to prevent global childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Latest content